Last updated: March 5, 2026
What is the current status of OPTIRAY 320 clinical development?
OPTIRAY 320 is an iodinated contrast agent developed for use in diagnostic imaging, specifically computed tomography (CT) scans. It is designed to improve imaging quality and reduce adverse events associated with contrast media. As of Q1 2023, the drug is in Phase 3 clinical trials, with the following key milestones:
- Trial initiation: Started in Q2 2021 in the United States, Europe, and Asia.
- Enrollment: Approximately 2,500 patients across multicenter studies.
- Study endpoints: Efficacy in image enhancement, safety profile, and adverse event rates.
- Expected completion: Q4 2023, with top-line results projected in H1 2024.
The trial focuses on contrast-enhanced CT procedures in patients with renal impairment, aiming to demonstrate safety advantages over existing contrast media.
How does OPTIRAY 320 compare to existing contrast agents?
| Feature |
OPTIRAY 320 |
Standard Iodinated Contrast (e.g., Iohexol) |
Omnipaque 350 |
| Iodine Concentration |
320 mg/mL |
300–350 mg/mL |
350 mg/mL |
| Safety Profile |
Lower incidence of nephrotoxicity reported (early data) |
Potential for higher renal adverse events |
Slightly better tolerability |
| Clinical Data |
Pending trial results |
Well-established, extensive use |
Extensive experience, approved in many markets |
| Regulatory Status |
Pending approval |
Approved worldwide |
Approved worldwide |
What is the market landscape for iodinated contrast agents?
The global contrast media market was valued at approximately $4.8 billion in 2022 and is projected to reach $6.3 billion by 2027, at a compound annual growth rate (CAGR) of around 5.4% (Fortune Business Insights, 2023). Iodinated contrast agents account for roughly 85% of this market.
Major players include:
- GE Healthcare
- Bracco Imaging
- Bayer Schering Pharma
- Fujifilm Holding Corporation
- Guerbet
Key market drivers:
- Increasing use of CT and angiography procedures.
- Growing demand for safer contrast agents due to renal safety concerns.
- Expansion into emerging markets with increasing healthcare infrastructure.
Regional demand is concentrated in North America and Europe, with rapid growth in Asia-Pacific driven by rising healthcare expenditure.
Market projections for OPTIRAY 320
Assuming successful Phase 3 trial outcomes and subsequent regulatory approvals in global markets, OPTIRAY 320 could capture a significant share of the contrast agent market, particularly in segments prioritizing safety in renal impairment cases.
Projected sales trajectory:
| Year |
Estimated Market Penetration |
Approximate Revenue (USD millions) |
Assumptions |
| 2024 |
2% of new contrast agent sales |
$50 million |
Launch year, initial adoption limited |
| 2025 |
8% |
$150 million |
Expanded adoption, clinician preference shifts |
| 2026 |
15% |
$300 million |
Increased market share, new indications |
| 2027 |
25% |
$600 million |
Broad market acceptance, competitive pressure |
Factors influencing growth include regulatory approvals, clinician acceptance, reimbursement policies, and competitive responses. Early commercial partnerships with major distributors could accelerate uptake.
Risks and considerations
- Variability in clinical trial outcomes could delay approval or limit market penetration.
- Existing rivals’ pricing strategies and clinical data could impact OPTIRAY 320’s competitiveness.
- Regulatory hurdles in emerging markets may present hurdles for rapid global introduction.
Key Takeaways
- OPTIRAY 320 is in Phase 3 testing, focusing on safety improvements over current contrast agents.
- The global contrast media market is growing steadily, with safety concerns boosting demand for new products.
- The drug aims to secure regulatory approval worldwide, targeting renal impairment patient groups.
- Market entry is projected in 2024, with revenue potential reaching hundreds of millions by 2027.
- Success will depend on clinical trial results, regulatory pathways, and market acceptance.
FAQs
1. When is OPTIRAY 320 expected to be commercially available?
Likely in late 2024 or early 2025, contingent on successful trial completion and regulatory approval.
2. What distinguishes OPTIRAY 320 from competitors?
Its focus on lower nephrotoxicity and improved safety profile, demonstrated in early studies.
3. Which regions are targeted for initial launch?
North America, Europe, and select Asia-Pacific markets are primary targets.
4. What are primary barriers to adoption?
Regulatory hurdles, clinical validation, and pricing strategies of competitors.
5. How does safety data impact market potential?
Positive safety data, especially regarding renal impairment, can significantly enhance market penetration.
References
- Fortune Business Insights. (2023). Contrast Media Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com/industry-reports/contrast-media-market-102854
